STAT3是乳腺癌癌基因的转录激活因子，这表明它可能是乳腺癌的潜在治疗靶点。因此，本研究通过具有患者特异性原代细胞（PSPC）的新型临床前平台，探讨了STAT3信号通路抑制剂C188-9在乳腺癌治疗中的潜在应用。PSPC是从获得的乳腺癌样本中分离出来的通过来自 15 名患者捐赠者的活检或手术，并得到他们的充分认可。 PSPCs用C188-9或其他化疗剂处理，然后用细胞活力测定进行分析。 Western blot法和实时定量PCR检测相应PSPCs STAT3信号通路的表达和活性。正常（实验）浓度的C188-9处理对PSPCs增殖具有有效的抑制作用。同时，与一些其他传统化疗药物相比，长时间使用低（临床相关）浓度的 C188-9 治疗会降低 PSPC 的细胞活力。此外，C188-9 降低了部分而非所有患者样本的 PSPC 中 pSTAT3 的表达水平。 C188-9 的治疗通过抑制 STAT3 至 C-myc 信号通路来降低乳腺癌样本的细胞活力。在这项研究中，我们测试了一种低临床相关浓度的新药 C188-9，以及几种传统药物。化疗药物。十五名患者捐献者中有十名的 PSPC 对 C188-9 敏感，而一些传统化疗药物却失败了。这一发现表明，C188-9 只能对这 10 名 PSPC 患者捐赠者产生治疗效果，表明未来 PSPC 的个性化利用。© 2024。作者。

STAT3 is a transcriptional activator of breast cancer oncogenes, suggesting that it could be a potential therapeutic target for breast cancer. Therefore, this study investigated the potential application of C188-9, a STAT3 signal pathway inhibitor, in the treatment of breast cancer through a novel pre-clinical platform with patient-specific primary cells (PSPCs).PSPCs were isolated from breast cancer samples obtained via biopsy or surgery from fifteen patient donors with their full acknowledgements. PSPCs were treated with C188-9 or other chemotherapeutic agents, and then analyzed with cell viability assay. Western blot assay and real-time quantitative PCR were also used to determine the expression and activity of STAT3 signaling pathway of corresponding PSPCs.C188-9 treatment at normal (experimental) concentration had valid inhibition on PSPCs proliferation. Meanwhile, treatment at a low (clinic-relevant) concentration of C188-9 for an extended period reduced cell viability of PSPCs still more than some of other traditional chemotherapy drugs. In addition, C188-9 decreased expression level of pSTAT3 in PSPCs from some, but not all patient samples. The treatment of C188-9 reduced cell viability of the breast cancer samples through inhibiting the STAT3 to C-myc signaling pathway.In this study, we tested a novel drug C188-9 at a low, clinic-relevant concentration, together with several traditional chemotherapy agents. PSPCs from ten out of fifteen patient donors were sensitive to C188-9, while some of traditional chemotherapy agents failed. This finding suggested that C188-9 could have treatment effects only on those ten PSPC patient donors, indicating the future personalized utilization of PSPCs.© 2024. The Author(s).